Active ingredient: risankizumab-rzaa
Diseases: psoriasis, other inflammatory disorders
Peak sales estimate: $3 billion to $5 billion
Approved: April 23, 2019
The scoop: In the spring, AbbVie got on the market a direct competitor to Johnson & Johnson's Tremfya, and analysts say it might just be best-in-class. The psoriasis drug, with the nearly unpronounceable name Skyrizi, was the first IL-23 drug to hit after Tremfya and Sun's Ilumya. While in a crowded market, Skyrizi “should benefit from … best-in-category efficacy,” SVB Leerink analyst Geoffrey Porges wrote in a note to clients after its April approval, calling out “stellar” phase 3 results that showed Skyrizi could clear skin lesions by 90% in up to three-quarters of patients within a week. And the AbbVie drug did that with less frequent dosing than Tremfya, which requires maintenance doses every eight weeks. — Ben Adams.